PCSK9 and type 2 diabetes mellitus: Furthermore, clinical trials showed that PCSK9 inhibitors did not increase the risk of onset-diabetes [14, 15], whereas genetics studies exhibited a link between PCSK9 genetic variants and risk of type 2 diabetes [16, 17].